【中新健康讯】广州，4月8日（记者 蔡敏婕）——粤港澳大湾区的生物医药产业再添新翼，全球领先的肿瘤创新企业百济神州有限公司今日在广州宣布，其抗体偶联药物(ADC)生产园区正式竣工并启用。这一举措将进一步提升大湾区在ADC药物研发和生产领域的影响力，为全球的医疗创新注入新动力。
百济神州广州生物药生产基地的ADC生产园区，旨在为ADC药物的临床试验和商业化生产提供全方位支持。园区的启用，不仅意味着百济神州自身研发的创新药物能够加速推进上市进程，同时也为其他生物医药企业提供了合作与交流的平台，共同促进ADC药物的研发进程。
ADC药物作为一种新型的癌症治疗手段，因其精准靶向肿瘤细胞的特性，近年来在肿瘤治疗领域备受瞩目。百济神州的这一重大投资，无疑将强化粤港澳大湾区在全球生物医药创新版图中的地位，同时也展现出中国在高端医疗技术领域的持续进步和开放合作的态度。
百济神州相关负责人表示，公司将借助这一全新的生产园区，致力于推动ADC药物的研发与产业化，为全球患者带来更有效的治疗方案。他们期待与大湾区内外的合作伙伴共同探索，以科技创新驱动医疗进步，改善癌症患者的生存质量。
此次ADC生产园区的启用，是百济神州在中国市场深化布局的重要一步，也是粤港澳大湾区生物医药产业发展的又一里程碑。随着更多类似项目的落地，大湾区有望成为全球生物医药创新的重要策源地，为全球健康事业贡献力量。
英语如下：
**News Title:** “Beigene Launches ADC Manufacturing Campus in Guangzhou, Boosting Biopharmaceutical Innovation in Greater Bay Area”
**Keywords:** ADC Campus, Beigene, Greater Bay Area Pharma
**News Content:**
**[China New Health News, Guangzhou, April 8 (Reporter蔡敏婕)]** The biopharmaceutical industry in the Greater Bay Area gains a new boost as Beigene Ltd., a global leader in cancer innovation, announces the completion and inauguration of its Antibody-Drug Conjugate (ADC) production campus in Guangzhou today. This move enhances the region’s influence in ADC drug research and manufacturing, injecting fresh momentum into global medical innovation.
The ADC production campus at Beigene’s Guangzhou Biologics Manufacturing Site is designed to provide comprehensive support for ADC drug clinical trials and commercial production. Its launch signifies an acceleration in the approval process for Beigene’s in-house innovative drugs and establishes a platform for collaboration and exchange among other biopharmaceutical companies, fostering joint progress in ADC drug development.
ADC drugs, known for their targeted approach to cancer cells, have garnered significant attention in the oncology field in recent years. Beigene’s substantial investment strengthens the Greater Bay Area’s position in the global biopharmaceutical innovation landscape and demonstrates China’s ongoing advancements and open collaboration in high-end medical technologies.
A Beigene representative stated that the company will leverage this new facility to drive ADC drug development and industrialization, striving to bring more effective treatment options to patients worldwide. They look forward to collaborating with partners within and beyond the Greater Bay Area to explore innovations driving medical progress and improve the quality of life for cancer patients.
The opening of the ADC production campus marks a significant step in Beigene’s strategic expansion in the Chinese market and adds another milestone to the development of the Greater Bay Area’s biopharmaceutical industry. With the implementation of more such projects, the region is poised to become a major hub for global biopharmaceutical innovation, contributing to global health initiatives.
【来源】http://www.chinanews.com/sh/2024/04-08/10194992.shtml
Views: 1